NO802497L - Fremgangsmaate for fremstilling av et veterinaerpreparat - Google Patents
Fremgangsmaate for fremstilling av et veterinaerpreparatInfo
- Publication number
- NO802497L NO802497L NO802497A NO802497A NO802497L NO 802497 L NO802497 L NO 802497L NO 802497 A NO802497 A NO 802497A NO 802497 A NO802497 A NO 802497A NO 802497 L NO802497 L NO 802497L
- Authority
- NO
- Norway
- Prior art keywords
- preparation
- group
- stated
- compound
- animals
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 29
- 238000000034 method Methods 0.000 title claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 49
- 241001465754 Metazoa Species 0.000 claims description 42
- 206010012735 Diarrhoea Diseases 0.000 claims description 21
- 230000000694 effects Effects 0.000 claims description 11
- 239000005526 vasoconstrictor agent Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000003651 drinking water Substances 0.000 claims description 7
- 235000020188 drinking water Nutrition 0.000 claims description 7
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 239000000695 adrenergic alpha-agonist Substances 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 239000008215 water for injection Substances 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- 125000002619 bicyclic group Chemical group 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical group C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 claims description 2
- 125000002950 monocyclic group Chemical group 0.000 claims description 2
- 239000000446 fuel Substances 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000005303 weighing Methods 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- DJDFFEBSKJCGHC-UHFFFAOYSA-N Naphazoline Chemical compound Cl.C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 DJDFFEBSKJCGHC-UHFFFAOYSA-N 0.000 description 6
- 239000000147 enterotoxin Substances 0.000 description 6
- 231100000655 enterotoxin Toxicity 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000000369 enteropathogenic effect Effects 0.000 description 5
- RRHJHSBDJDZUGL-UHFFFAOYSA-N lidamidine Chemical compound CN=C(N)NC(=O)NC1=C(C)C=CC=C1C RRHJHSBDJDZUGL-UHFFFAOYSA-N 0.000 description 5
- 229960005045 lidamidine Drugs 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 241000282887 Suidae Species 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 230000001142 anti-diarrhea Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 229960004760 naphazoline hydrochloride Drugs 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- BYJAVTDNIXVSPW-UHFFFAOYSA-N tetryzoline Chemical compound N1CCN=C1C1C2=CC=CC=C2CCC1 BYJAVTDNIXVSPW-UHFFFAOYSA-N 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 101710146739 Enterotoxin Proteins 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 206010022998 Irritability Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- CNIIGCLFLJGOGP-UHFFFAOYSA-N SJ000285664 Natural products C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- HUCJFAOMUPXHDK-UHFFFAOYSA-N Xylometazoline Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCCN1 HUCJFAOMUPXHDK-UHFFFAOYSA-N 0.000 description 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 2
- 229960003022 amoxicillin Drugs 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000003874 central nervous system depressant Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000002011 intestinal secretion Anatomy 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 229960005016 naphazoline Drugs 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 229960000337 tetryzoline Drugs 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- YGWFCQYETHJKNX-UHFFFAOYSA-N 2-[(4-tert-butyl-2,6-dimethylphenyl)methyl]-4,5-dihydro-1h-imidazol-3-ium;chloride Chemical compound [Cl-].CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCC[NH2+]1 YGWFCQYETHJKNX-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- ZNIFSRGNXRYGHF-UHFFFAOYSA-N Clonidine hydrochloride Chemical compound Cl.ClC1=CC=CC(Cl)=C1NC1=NCCN1 ZNIFSRGNXRYGHF-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229960002925 clonidine hydrochloride Drugs 0.000 description 1
- 229940078069 clonidine injection Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 239000007970 homogeneous dispersion Substances 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229940090044 injection Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- -1 methoxy, hydroxy Chemical group 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 239000000133 nasal decongestant Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 229960000833 xylometazoline Drugs 0.000 description 1
- 229960001095 xylometazoline hydrochloride Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB7929434 | 1979-08-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO802497L true NO802497L (no) | 1981-02-24 |
Family
ID=10507398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO802497A NO802497L (no) | 1979-08-23 | 1980-08-22 | Fremgangsmaate for fremstilling av et veterinaerpreparat |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US4332814A (fr) |
| EP (2) | EP0025269B1 (fr) |
| JP (1) | JPS5634628A (fr) |
| AU (1) | AU533436B2 (fr) |
| CA (1) | CA1156147A (fr) |
| DE (1) | DE3071229D1 (fr) |
| DK (1) | DK363180A (fr) |
| ES (1) | ES494433A0 (fr) |
| GR (1) | GR69871B (fr) |
| IE (1) | IE51143B1 (fr) |
| IL (1) | IL60809A0 (fr) |
| NO (1) | NO802497L (fr) |
| NZ (1) | NZ194591A (fr) |
| ZA (1) | ZA804795B (fr) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0025269B1 (fr) * | 1979-08-23 | 1985-11-13 | Beecham Group Plc | Composition vétérinaire contre la diarrhée |
| DE3168754D1 (en) * | 1980-07-09 | 1985-03-21 | Beecham Group Plc | Clonidine derivatives useful in the treatment of diarrhoea |
| DE3360148D1 (en) * | 1982-02-10 | 1985-06-05 | Beecham Group Plc | Guanidine derivatives |
| GB8313588D0 (en) * | 1983-05-17 | 1983-06-22 | Beecham Group Plc | Compounds |
| US4714707A (en) * | 1984-01-13 | 1987-12-22 | Rorer Pharmaceutical Corporation | Aryl substituted heterocycles for treating gastrointestinal motility dysfunction |
| DE3428342A1 (de) * | 1984-08-01 | 1986-02-13 | Boehringer Ingelheim Vetmedica GmbH, 6507 Ingelheim | Futtermittelzusatz zur verbesserung des wachstums bei landwirtschaftlichen nutztieren |
| US5171575A (en) * | 1987-01-19 | 1992-12-15 | Nisshin Flour Milling Co., Ltd. | Process for preventing diarrhea in animals |
| CA1321751C (fr) * | 1989-02-21 | 1993-08-31 | Eugene C. Crichlow | Mecanisme mediatisant la stase ruminale dans l'acidose lactique ruminale |
| US5352691A (en) * | 1993-02-16 | 1994-10-04 | Thomas Peter G | Effective treatment modality for adult respiratory distress syndrome using L-histidine |
| US5576437A (en) * | 1993-12-17 | 1996-11-19 | The Procter & Gamble Company | 7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists |
| US5578607A (en) * | 1993-12-17 | 1996-11-26 | The Procter & Gamble Company | 6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists |
| AU699041B2 (en) * | 1993-12-17 | 1998-11-19 | Board Of Regents Of The University Of Nebraska, The | 6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists |
| DK0735877T3 (da) * | 1993-12-17 | 2000-11-06 | Procter & Gamble | 6-(2-imidazolinylamino)quinoxalinforbindelser, der er egnede som alfa-2-adrenoceptoragonister. |
| US5478858A (en) * | 1993-12-17 | 1995-12-26 | The Procter & Gamble Company | 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists |
| US5869458A (en) * | 1994-10-14 | 1999-02-09 | Waite; Christopher S. | Frozen rehydration formulation and delivery system therefor |
| EP0827393B1 (fr) * | 1995-05-23 | 2002-10-30 | SmithKline Beecham plc | Composition pharmaceutique preparee par ajout d'un vecteur aromatisant a un medicament |
| US5916900A (en) | 1995-06-29 | 1999-06-29 | The Procter & Gamble Company | 7-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists |
| US5741807A (en) * | 1996-09-27 | 1998-04-21 | Cytos Pharmaceuticals, L.P. | Histidine compositions and methods for treating or preventing infectious and non-infectious diarrheas |
| CN1284073A (zh) | 1997-11-24 | 2001-02-14 | 宝洁公司 | 5－(2－咪唑啉基氨基)－苯并咪唑衍生物,其制备和作为具有改进的代谢稳定性的a－肾上腺素能受体激动剂的应用 |
| US20040071793A1 (en) * | 2002-10-05 | 2004-04-15 | Bobrowski Paul J. | Oral rehydration methods and compositions |
| US20050136105A1 (en) * | 2003-12-22 | 2005-06-23 | Allen Marni L. | Consumer customized dosage forms |
| US7371405B2 (en) * | 2003-12-22 | 2008-05-13 | Mcneil-Ppc, Inc. | Consumer customized dosage forms |
| TW200806282A (en) * | 2006-05-05 | 2008-02-01 | Wyeth Corp | Solid dosage formulations |
| KR200466495Y1 (ko) * | 2010-12-14 | 2013-04-23 | 황연지 | 좌변기용 어린이 다리 받침장치 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2731471A (en) * | 1956-01-17 | Nxg hi | ||
| US2842478A (en) * | 1955-08-25 | 1958-07-08 | Pfizer & Co C | Tetrahydrozoline-central nervous system depressant veterinary compositions and method of using same |
| FR1217629A (fr) * | 1956-07-10 | 1960-05-04 | Ciba Geigy | Procédé de préparation de la 2-(p-tertio-butyl-o,o'-diméthyl-phényl-méthyl)-imidazoline et de ses sels |
| US2915431A (en) * | 1956-07-17 | 1959-12-01 | Lab Robert & Carriere Sa Des | 2-(2'-isopropyl-4'-chloro-5'-methyl)-phenoxymethyl-2-imidazoline and its pharmaceutical uses |
| NL286080A (fr) * | 1961-11-30 | |||
| BE754935A (fr) * | 1969-08-13 | 1971-02-17 | Hoechst Ag | 2-(thienyl-3'-amino)-1,3-diazacycloalcenes et leur preparation |
| SE7407022L (fr) * | 1973-06-06 | 1974-12-09 | Wander Ag Dr A | |
| NZ183492A (en) * | 1976-03-27 | 1980-04-28 | Beecham Group Ltd | Veterinary rehydration compositions containing monosaccharide amino acid and citric acid or citrate |
| CA1072962A (fr) | 1976-08-11 | 1980-03-04 | George H. Douglas | Procede pour la preparation d'amidinourees |
| US4122190A (en) * | 1976-10-04 | 1978-10-24 | Sandoz Ltd. | Treating acromegaly |
| EP0025269B1 (fr) * | 1979-08-23 | 1985-11-13 | Beecham Group Plc | Composition vétérinaire contre la diarrhée |
| US4312879A (en) * | 1980-08-14 | 1982-01-26 | Richardson-Merrell Inc. | Clonidine and lofexidine as antidiarrheal agents |
-
1980
- 1980-08-04 EP EP80302647A patent/EP0025269B1/fr not_active Expired
- 1980-08-04 DE DE8080302647T patent/DE3071229D1/de not_active Expired
- 1980-08-04 EP EP83101136A patent/EP0086428B1/fr not_active Expired
- 1980-08-07 NZ NZ194591A patent/NZ194591A/xx unknown
- 1980-08-08 IL IL60809A patent/IL60809A0/xx unknown
- 1980-08-11 US US06/177,365 patent/US4332814A/en not_active Expired - Lifetime
- 1980-08-17 ZA ZA00804795A patent/ZA804795B/xx unknown
- 1980-08-19 CA CA000358579A patent/CA1156147A/fr not_active Expired
- 1980-08-21 AU AU61631/80A patent/AU533436B2/en not_active Ceased
- 1980-08-21 GR GR62714A patent/GR69871B/el unknown
- 1980-08-22 JP JP11578080A patent/JPS5634628A/ja active Pending
- 1980-08-22 DK DK363180A patent/DK363180A/da not_active Application Discontinuation
- 1980-08-22 NO NO802497A patent/NO802497L/no unknown
- 1980-08-22 ES ES494433A patent/ES494433A0/es active Granted
- 1980-08-22 IE IE1776/80A patent/IE51143B1/en unknown
-
1982
- 1982-02-19 US US06/350,403 patent/US4520014A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| GR69871B (fr) | 1982-07-20 |
| JPS5634628A (en) | 1981-04-06 |
| IE801776L (en) | 1981-02-23 |
| IL60809A0 (en) | 1980-10-26 |
| IE51143B1 (en) | 1986-10-15 |
| EP0025269B1 (fr) | 1985-11-13 |
| US4520014A (en) | 1985-05-28 |
| EP0086428B1 (fr) | 1987-07-29 |
| AU533436B2 (en) | 1983-11-24 |
| US4332814A (en) | 1982-06-01 |
| NZ194591A (en) | 1983-06-17 |
| DE3071229D1 (en) | 1985-12-19 |
| EP0086428A1 (fr) | 1983-08-24 |
| ES8106486A1 (es) | 1981-07-01 |
| AU6163180A (en) | 1981-04-09 |
| ES494433A0 (es) | 1981-07-01 |
| DK363180A (da) | 1981-02-24 |
| ZA804795B (en) | 1981-07-29 |
| CA1156147A (fr) | 1983-11-01 |
| EP0025269A1 (fr) | 1981-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO802497L (no) | Fremgangsmaate for fremstilling av et veterinaerpreparat | |
| Wolff et al. | Efficacy of triclabendazole against Fasciola hepatica in sheep and goats | |
| Karriker et al. | Drug pharmacology, therapy, and prophylaxis | |
| CN101953841B (zh) | 一种抗猪附红细胞体病的复方长效土霉素注射液及其制备方法 | |
| US20020103261A1 (en) | Compositions for injection or intravenous administration for the treatment of internal infection or inflammation in humans and animals | |
| EP0692964B1 (fr) | Polymeres ionenes utilises comme anthelminthiques chez l'animal | |
| CN101987100A (zh) | 一种硫酸头孢喹肟混悬注射液的制备方法 | |
| CN101516194A (zh) | 减轻神经元细胞损害的方法 | |
| CN101579347B (zh) | 治疗泌乳期奶牛乳房炎的乳房灌注剂及其制备方法 | |
| CN104688683A (zh) | 一种阿苯达唑混悬剂及其制备方法 | |
| CA3105082A1 (fr) | Compositions d'associations de cannabidiol | |
| CN103908670B (zh) | 一种治疗畜禽大肠杆菌感染疾病的复方组合物 | |
| CA2654082C (fr) | Utilisation de microparticules de soufre pour la prevention et le traitement de pathologies chez l'humain et les animaux | |
| CN103721240A (zh) | 一种治疗畜禽消化道细菌性感染的复方制剂及其制备方法 | |
| CN106539754A (zh) | 氢溴酸常山酮溶液及其制备方法 | |
| CN103536603B (zh) | 一种可湿性磺胺间甲氧嘧啶(钠)粉剂及其制备方法 | |
| US20200054670A1 (en) | Method and use of compositions comprising lignosulfonate and substantially free of elemental sulphur for pathogenic attenuation | |
| EP0059057A1 (fr) | Traitement de la diarrhée | |
| EP0112061A2 (fr) | Composition pharmaceutique et vétérinaire contenant du guanoxabenz | |
| JPH0471890B2 (fr) | ||
| CN103919861B (zh) | 防治仔猪大肠杆菌病的中西药复方透皮乳剂及其制备方法 | |
| KR20220041862A (ko) | 크립토스포리듐증의 예방 및/또는 치료를 위한 수의학적 조성물 | |
| NZ204129A (en) | Treating infective keratoconjunctivitis in animals using cloxacillin salt | |
| US3592894A (en) | Treatment of intestinal helminthiasis with tetrachlorofulvenes | |
| RU1751890C (ru) | Препарат для лечения колибактериоза телят "ромиксин" |